ECE2024 Eposter Presentations Calcium and Bone (102 abstracts)
National Medical Institute of the Ministry of the Interior and Administration in Warsaw, Warszawa, Poland
Background: The alterations in collagen synthesis and connective tissue structure that occur in EhlersDanlos syndrome translate to an increased risk of bone mass loss and development of osteopenia and osteoporosis, which may be evaluated with bone turnover biomarkers. Some subtypes of EhlersDanlos syndrome are associated with structural alterations in the extracellular matrix glycoprotein tenascin-X. The purpose of this study was to assess the relationship between tenascin-X and both bone turnover markers and bone mineral density (BMD) in patients with EhlersDanlos syndrome.
Material and methods: This study involved a prospective evaluation of 30 female patients, aged 2053 years, with hypermobile or classical EhlersDanlos syndrome. All patients underwent tests of their tenascin-X levels, calcium and phosphorus metabolism parameters, and BMD scans of the femoral neck and lumbar spine.
Results: The study showed no significant correlation between tenascin-X levels on one hand and femoral neck BMD (rs 0.13, P=0.49), lumbar spine BMD (rs 0.17, P=0.36), alkaline phosphatase levels (rs 0.18, P=0.33), beta-crossLaps levels (rs 0.11, P=0.56), or osteocalcin levels (rs -0.08, P=0.66). Univariate logistic regression showed no statistically significant effect of tenascin-X levels on the development of osteoporosis (OR 0.48, 95% CI 01.32, P=0.99).
Conclusions: Tenascin-X does not show significant correlation with either bone turnover markers or BMD in females with EhlersDanlos syndrome.